A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer (Q42492202)

1 November 2017

title

A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer (English)

1 reference

1 November 2017

4

Keiichi Fujiwara

1 reference

1 November 2017

author name string

Josep María Del Campo

1

1 reference

1 November 2017

Michael Birrer

2

1 reference

1 November 2017

Craig Davis

3

1 reference

1 November 2017

Ashwin Gollerkeri

5

1 reference

1 November 2017

Martin Gore

6

1 reference

1 November 2017

Brett Houk

7

1 reference

1 November 2017

Susie Lau

8

1 reference

1 November 2017

Andres Poveda

9

1 reference

1 November 2017

Antonio González-Martín

10

1 reference

1 November 2017

Carolyn Muller

11

1 reference

1 November 2017

Kei Muro

12

1 reference

1 November 2017

Kristen Pierce

13

1 reference

1 November 2017

Mie Suzuki

14

1 reference

1 November 2017

Jennifer Vermette

15

1 reference

1 November 2017

Amit Oza

16

1 reference

1 November 2017

language of work or name

English

0 references

publication date

18 April 2016

1 reference

1 November 2017

1 reference

1 November 2017

volume

142

1 reference

1 November 2017

issue

1

1 reference

1 November 2017

page(s)

62-69

1 reference

Emerging therapeutic targets in endometrial cancer

1 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2016.04.019

7 January 2021

Phosphoinositide kinases

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2016.04.019

Mutational analysis of gene families in human cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2016.04.019

Stathmin overexpression identifies high-risk patients and lymph node metastasis in endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2016.04.019

Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2016.04.019

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2016.04.019

PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2016.04.019

Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2016.04.019

Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2016.04.019

First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2016.04.019

Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2016.04.019

Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2016.04.019

Novel agents and associated toxicities of inhibitors of the pi3k/Akt/mtor pathway for the treatment of breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2016.04.019

New strategies in endometrial cancer: targeting the PI3K/mTOR pathway--the devil is in the details

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2016.04.019

Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2016.04.019

10.1016/J.YGYNO.2016.04.019

7 January 2021

Identifiers

DOI

1 reference

1 November 2017

1 reference